Phase III study of Saxenda in adolescent obesity published in New England Journal of Medicine.- Novo Nordisk
Related news and insights
Detailed results from Eli Lilly and Company's phase III SURMOUNT-1 clinical trial evaluating tirzepatide for the treatment of obesity or overweight were simultaneously published in The New England Journal of Medicine (NEJM) and presented in a symposium sponsored by the American Diabetes Association(ADA) during the ADA's 82nd Scientific Sessions.
LY 3298176 (tirzepatide 5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly's phase III SURMOUNT-1 clinical trial, with participants losing up to 22.5% (52 lb. or 24 kg) of their body weight for the efficacy estimand.
Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Wegovy for chronic weight management in adults with obesity.